U.S. pharma large copyright scrapped two experimental weight loss capsules past calendar year—a after-daily tablet, lotiglipron, on account of elevated liver enzymes along with a twice-day by day pill, danuglipron, as a consequence of powerful Unwanted side effects—but CEO Albert Bourla has said the company is determined to “Engage in and ear